Market Overview

UPDATE: Piper Jaffray Upgrades Myriad Genetics to Overweight on Reimbursement Strategy Confidence

Share:
Related MYGN
Benzinga's Top Upgrades, Downgrades For October 2, 2017
15 Biggest Mid-Day Gainers For Friday

Piper Jaffray raised its rating on Myriad Genetics (NASDAQ: MYGN) from Neutral to Overweight and increased its price target from $28 to $35.

Piper Jaffray commented, "Management expressed a high level of confidence in their reimbursement strategy, citing multiple layers of stability and a tight range around their median rates (specifically Medicaid and managed care). Additionally, we believe Myriad's longer-term strategy to combat generic BRCAnalysis tests by expanding its panel beyond BRCA 1/2, capturing a larger percentage of heredity cancer has shades of the old, but successful, intellectual property HPV argument. Based on our diligence, management's comments and an updated DCF scenario analysis, we see the risk premium the market currently ascribes as excessive."

Myriad Genetics closed at $26.95 on Friday.

Latest Ratings for MYGN

DateFirmActionFromTo
Oct 2017Morgan StanleyMaintainsUnderweight
Oct 2017Leerink SwannInitiates Coverage OnMarket Perform
Aug 2017Deutsche BankUpgradesSellHold

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...